Sutro Biopharma Reports Full Year 2020 Financial Results and Provides Business Highlights and 2021 Anticipated Milestones
– Year-end 2020 cash, cash equivalents and marketable securities of $326.5 million, with projected runway
– Year-end 2020 cash, cash equivalents and marketable securities of $326.5 million, with projected runway